

This is a repository copy of *Hierarchical network meta-analysis models for synthesis of evidence from randomised and non-randomised studies*.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/198622/>

Version: Published Version

Article:

Hussein, Humaira, Abrams, Keith R, Gray, Laura J et al. (3 more authors) (2023)

Hierarchical network meta-analysis models for synthesis of evidence from randomised and non-randomised studies. *BMC Medical Research Methodology*. 97. ISSN 1471-2288

<https://doi.org/10.1186/s12874-023-01925-5>

Reuse

This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here:

<https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.

RESEARCH

Open Access



Hierarchical network meta-analysis models for synthesis of evidence from randomised and non-randomised studies

Humaira Hussein¹, Keith R. Abrams^{2,3}, Laura J. Gray¹, Sumayya Anwer⁴, Sofia Dias⁴ and Sylwia Bujkiewicz^{1*}

Abstract

Background With the increased interest in the inclusion of non-randomised data in network meta-analyses (NMAs) of randomised controlled trials (RCTs), analysts need to consider the implications of the differences in study designs as such data can be prone to increased bias due to the lack of randomisation and unmeasured confounding. This study aims to explore and extend a number of NMA models that account for the differences in the study designs, assessing their impact on the effect estimates and uncertainty.

Methods Bayesian random-effects meta-analytic models, including naïve pooling and hierarchical models differentiating between the study designs, were extended to allow for the treatment class effect and accounting for bias, with further extensions allowing for bias terms to vary depending on the treatment class. Models were applied to an illustrative example in type 2 diabetes; using data from a systematic review of RCTs and non-randomised studies of two classes of glucose-lowering medications: sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists.

Results Across all methods, the estimated mean differences in glycated haemoglobin after 24 and 52 weeks remained similar with the inclusion of observational data. The uncertainty around these estimates reduced when conducting naïve pooling, compared to NMA of RCT data alone, and remained similar when applying hierarchical model allowing for class effect. However, the uncertainty around these effect estimates increased when fitting hierarchical models allowing for the differences in study design. The impact on uncertainty varied between treatments when applying the bias adjustment models. Hierarchical models and bias adjustment models all provided a better fit in comparison to the naïve-pooling method.

Conclusions Hierarchical and bias adjustment NMA models accounting for study design may be more appropriate when conducting a NMA of RCTs and observational studies. The degree of uncertainty around the effectiveness estimates varied depending on the method but use of hierarchical models accounting for the study design resulted in increased uncertainty. Inclusion of non-randomised data may, however, result in inferences that are more generalisable and the models accounting for the differences in the study design allow for more detailed and appropriate modelling of complex data, preventing overly optimistic conclusions.

Keywords Real world evidence, Evidence synthesis, Hierarchical models, Bias adjustment

*Correspondence:

Sylwia Bujkiewicz
sylwia.bujkiewicz@le.ac.uk

Full list of author information is available at the end of the article



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Introduction

Network meta-analysis (NMA) is a widely used tool in health technology assessment (HTA) for the synthesis of direct and indirect evidence aiming to provide an overview of treatment effects [1]. Traditionally, NMAs have been carried out using data from randomised controlled trials (RCTs) as these have been considered the “gold-standard” for assessing effectiveness of interventions due to the randomisation techniques used and the strict criteria for inclusion/exclusion of individuals [2–4]. However, recently there has been an increased number of non-randomised observational and real-world studies conducted especially utilising large electronic health care databases. This has in turn highlighted an interest in including data from such studies in evidence synthesis, such as NMA, due to the epidemiological benefits they could provide [5]. However, such non-randomised data are considered to be inherently biased due to the lack of randomisation of individuals included and unmeasured confounding factors [1, 5]. If not accounted for, biased estimates from observational studies could in turn lead to biased estimates from the NMA, resulting in inappropriate conclusions drawn. Therefore, there is a growing need for methodological development and evaluation of methods for appropriate inclusion of non-randomised data in NMAs of RCTs and guidelines on such synthesis of data from randomised and non-randomised studies also begin to emerge [6].

Inclusion of non-randomised studies in evidence synthesis of RCT data has been considered for a number of reasons, typically either to allow for extension of evidence base when RCT data are sparse, looking to either improve the precision of the results or to bridge disconnected networks of RCT evidence, or to generalise the results to a broader population. A number of methods have been suggested to allow for inclusion of non-randomised data in NMAs of RCTs [5, 7–12]. Schmitz et al. [9] developed and compared a number of approaches, including naïve pooling, use of informative prior distributions and hierarchical models, by applying them to data in rheumatoid arthritis [9]. Schmitz et al. found that inclusion of observational evidence in NMA increased uncertainty of the pooled effectiveness estimates. Jenkins et al., who applied naïve pooling, a hierarchical model and power prior analysis to data in relapsing remitting multiple sclerosis, also obtained results with increased uncertainty compared to the analysis of RCT data alone, due to the increased between-study heterogeneity when incorporating data from non-randomised studies.

Bias, inherent in the observational data due to the lack of randomisation, has received a lot of consideration in the literature of methods for the analysis of individual participant data from observational studies [13]. The

issue of bias in the meta-analysis of aggregate level data, including non-randomised comparative studies, has also been investigated, but not explored extensively in the context of real world evidence. Begg and Pilote proposed a model for adjusting for bias when including non-randomised evidence in meta-analysis; however, non-randomised data considered in this method were limited to single-arm studies [14]. In the context of NMA, a bias adjustment model for meta-analysis of comparative data has been introduced by Dias et al. [15]; in this case considering the risk of bias within RCTs. Schmitz et al. included bias adjustment in their hierarchical model, adjusting for overestimation (or underestimation) in the observational studies using an additive random bias term applied to the mean, at the basic parameter level in NMA, or for over precision using a multiplicative factor applied to the variance [9]. Efthimiou et al. propose a design-adjusted evidence synthesis method which combines data from randomized and non-randomised studies after adjusting the treatment effect estimates from the non-randomised evidence [8]. The two above methods, by Schmitz et al. and Efthimiou et al., assume that only data from non-randomised sources are biased. Verde proposed a Bayesian mixture model for pairwise meta-analysis, allowing for the true treatment effects in the meta-analysis to be a mixture of biased and unbiased effects [10].

Whilst in this paper we did not intend to carry out a full review of the literature on combining RCT and non-RCT data, the aim of this study was to evaluate and extend a number of methods for inclusion of non-randomised data in a NMA of RCTs. The existing methods that we focussed on included naïve pooling, hierarchical models and bias adjustment models, discussed by Schmitz et al. [9]. We first explore the models which account for the hierarchy of the data in terms of the grouping of treatments within classes as well as considering the different designs of included studies (i.e., randomised and non-randomised). We then extend these hierarchical models to allow for the class effect in the hierarchical model of different study design. We also explore the hierarchical model with bias adjustment, introduced by Schmitz et al., allowing for the bias for the non-randomised studies to be introduced at the individual study level as a random effect and extend it to allow for the average bias to vary across treatment classes.

We applied the methods to an illustrative example in type 2 diabetes assessing the impact of treatments within two classes of glucose-lowering medications; sodium-glucose co-transporter 2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) [16]. We illustrate how the methods can be utilised to model data from studies of different designs in NMA in more

detail, and to explore the impact the modelling assumptions have on effect estimates and uncertainty.

Methods

Illustrative example

To illustrate the methods, we used an example in type 2 diabetes medications. Data were obtained from a systematic literature review of RCTs assessing the efficacy and safety of treatments within two classes of glucose lowering medications, SGLT-2is and GLP-1Ras, in individuals with type 2 diabetes undertaken by Hussein et al. [16]. The literature search from the review was repeated to identify non-randomised comparative studies conducted within the time-frame of the original systematic review (before April 2019). The evidence base for the NMA was further extended by including aggregate level data from the analysis of data from patients with type 2 diabetes included in the Clinical Practice Research Datalink. Data on the treatment effects of the medications included the mean change in HbA1c (%) from baseline after 24 (± 8 weeks) and 52 weeks (± 8 weeks).

Basic network meta-analysis

The basic NMA random-effects model is as follows. The mean change in HbA1c, y_{ik} , in trial i and arm k is assumed to be approximately normally distributed with standard error se_{ik} and mean θ_{ik} :

$$y_{ik} \sim N\left(\theta_{ik}, se_{ik}^2\right) \tag{1}$$

Following a generalised linear model approach, an identity link function was used to model the true treatment effects (i.e. true mean differences from baseline), $\delta_{i,jk}$, between treatments in arm k and arm j in trial i , which are assumed to follow a normal distribution:

$$\theta_{ik} = \mu_{ij} + \delta_{i,jk} I_{\{k \neq j\}} \tag{2}$$

where

$$\delta_{i,jk} \sim N(d_{jk}, \sigma^2) \tag{3}$$

and μ_{ij} are the baseline treatment effects in each study i . The NMA models follow the assumption of consistency, which means that all studies would estimate the same relative effects if they had included all the treatments. This is modelled by expressing the mean treatment differences in terms of, so called, basic parameters (the effects of each treatment relative to a reference treatment in the network coded as treatment 1), i.e. $d_{jk} = d_{1k} - d_{1j}$. The assumption implies that the direct comparisons (where evidence exist from head-to-head studies for a given contrast) are exchangeable with indirect comparisons obtained using the above consistency rule.

Multi-arm adjustments were considered to account for the consistency between treatment comparisons within the same trial and correlation between treatment effects in comparison to the baseline treatment [10].

Following a Bayesian framework, prior distributions were placed on the parameters of the model in Eqs. (1)–(3). For example, we chose a non-informative uniform prior distribution for the heterogeneity parameter $\sigma \sim Uniform(0, 5)$, a “vague” normal prior distribution for the basic parameters $d_{1k} \sim N(0, 1000)$ and the baseline effects $\mu_{ij} \sim N(0, 10000)$. The model was initially applied to RCT data and data from non-randomised studies separately.

Shared parameter model

The data on treatment effects in our illustrative example have been reported using different formats: as either change from baseline within treatment arms or difference in change from baseline between treatment arms. To allow for the synthesis of all the relevant data, reported in such different ways, a shared parameter model was used following Dias et al. [7]. In addition to the model (1)–(2), representing the within-study model for the effects reported within treatment arms, we model the relative effects from studies reporting treatment differences between the treatment arms k and j as

$$y_{i,jk} \sim N\left(\delta_{i,jk}, se_{i,jk}^2\right) \tag{4}$$

The relative effects $\delta_{i,jk}$ represent the shared parameter between the models for the two data formats (see Eq. (2)). These true effects $\delta_{i,jk}$ are assumed exchangeable within treatment contrasts in the network as described in Eq. (3) for the basic NMA.

Network meta-analysis models for inclusion of non-randomised data

Model A – naïve pooling

The above basic NMA model, described by Eqs. (1)–(4), was applied to both RCT and non-randomised data combined, with no adjustments made for different sources of data or classes of treatments within the network.

Model B1 – two-level hierarchical model (treatment vs class)

The second type of model to be fitted was a two-level hierarchical model with treatments nested within treatment classes; i.e. treatments were nested within either SGLT-2i, GLP-1RA or placebo classes [17]. The model allows for borrowing of information across treatments within each class when estimating pooled treatment effects for individual treatments, which are of primary interest. It also allows for estimating an average effect within each treatment class, which may also be of

interest. Updating Eqs. (2) and (3) leads to the random-effects model, which reads:

$$\theta_{ik} = \mu_{ij} + \delta_{i,jk}^* I_{\{k \neq j\}}, \delta_{i,jk}^* \sim N(d_{jk}^*, \sigma^2) \tag{5}$$

where $d_{jk}^* = d_{1k,C} - d_{1j,C}$. The class-specific basic parameters $d_{1k,C}$ are assumed exchangeable:

$$d_{1k,C} \sim N(D_C, \sigma_C^2) \tag{6}$$

where D_C denotes the pooled treatment effect estimate for treatments in the class C of the interventions, relative to the reference treatment, and with between-treatment class-specific standard deviation σ_C^2 . As for the naïve pooling model A, this model was extended to the shared parameter model to account for the differences in the way outcomes were reported. Note that in our illustrative example, we assumed fixed effect for the placebo class, with a prior distribution for the basic parameter $d_{1,placebo} \sim N(0, 1000)$, due to the fact that this class included only a single treatment.

Prior distributions were placed on parameters on the model. Similarly as in Model A – naïve pooling, we chose the following prior distributions for the parameters in Eqs. (5) and (6): $\sigma \sim Uniform(0, 5)$, $\sigma_C \sim Uniform(0, 5)$, $D_C \sim N(0, 1000)$.

Model B2 – two-level hierarchical model (treatment vs design)

The third model we considered was a two-level hierarchical model, modelling the between-study heterogeneity of treatment effects within and across each study design (i.e. RCT and non-randomised studies). The model allows for differentiating between treatment effects from studies of different designs when estimating pooled treatment effects for individual treatments, which are of primary interest, and it allows for estimation of these average effects for each type of study design individually, and also overall across all studies (whilst taking into account of the across-design heterogeneity). Following the methods by Schmitz et al. [9];

$$\theta_{ik} = \mu_{ij} + \delta_{i,jk} I_{\{k \neq j\}}, \delta_{i,jk} \sim N(d_{jk}^{design}, \sigma^2) \tag{7}$$

where d_{jk}^{design} is the design specific average treatment effect of treatment k versus treatment j , with the mean $d_{jk}^{design} = d_{1k}^{design} - d_{1j}^{design}$. The design specific basic parameters follow a common distribution

$$d_{1k}^{design=RCT} \sim N(D_{1k}, \sigma_D^2) \text{ and } d_{1k}^{design=OBS} \sim N(D_{1k}, \sigma_D^2)$$

The following prior distributions were placed on parameters: $\sigma_D \sim Uniform(0, 5)$ and $D_{1k} \sim N(0, 1000)$.

Model B3 – three-level hierarchical model

This model was developed to extend the above two-level models (B1 and B2), by allowing for an additional level in the random-effects hierarchical NMA model to estimate the heterogeneity within study designs as well as estimating the heterogeneity within treatment classes in the network. Therefore, adapting the above model (7), the three-level hierarchical NMA model is as follows:

$$d_{1k}^{design=RCT} \sim N(D_{1k,C}, \sigma_D^2) \text{ and } d_{1k}^{design=OBS} \sim N(D_{1k,C}, \sigma_D^2)$$

to allow for the class specific mean effects, which, similar to Eq. (6), are assumed exchangeable within each treatment class

$$D_{1k,C} \sim N(D_C, \sigma_C^2).$$

Prior distributions were placed on the design level standard deviation σ_D , the class-specific standard deviations σ_C and the class-specific mean D_C in the same way as in the above two models.

Model C1 – bias adjustment assuming same bias by class

Observational studies are assumed to have additional risk of bias due to the absence of randomisation and unmeasured confounding. The bias adjustment model allows for this by including an additional bias parameter, β_i for observational studies [9]. By including this additional term, the NMA model takes the following form:

$$\theta_{ik} = \mu_{ij} + \delta_{i,jk} I_{\{k \neq j\}} + \beta_i I_{\{design\}} \tag{8}$$

where:

$$I_{\{design\}} = \begin{cases} 0 & \text{if design of study } i = RCT \\ 1 & \text{if design of study } i = OBS \end{cases}$$

The true effects $\delta_{i,jk}$ follow a common distribution within each treatment contrast as in (3). The bias terms β_i for each study i are assumed to follow a common distribution;

$$\beta_i \sim N(B, \kappa^2),$$

with mean B and standard deviation κ , which governs the extent to which different non-randomised studies vary in terms of the level of bias assumed. Non-informative prior distributions were placed on the following parameters: $\sigma \sim Uniform(0, 5)$, $d_{1k} \sim N(0, 1000)$, $B \sim N(0, 1000)$ and $\kappa \sim Uniform(0, 5)$.

Model C2 – bias adjustment assuming varying bias by class

The above bias adjustment model assumes exchangeable biases across all observational studies regardless of treatment class being compared; however, the level of bias may differ across classes. Therefore, the model in Eq. (8) was extended to allow for a different degree of bias depending on the treatment class; placebo/standard care, SGLT-2i or GLP-1RA, whilst assuming the variability of the biases across classes is the same:

$$\theta_{ik} = \mu_{ij} + \delta_{i,jk}I_{\{k \neq j\}} + \beta_{i,C}^*I_{\{design\}} \tag{9}$$

where $I_{\{design\}}$ is defined in the same way as in model (8), the true effects $\delta_{i,jk}$ follow a common distribution within each treatment contrast as in (3) and the biases are exchangeable within each treatment class;

$$\beta_{i,C}^* \sim N(B_C, \kappa^2)$$

with B_C denoting the pooled bias estimate for class C of the interventions. Prior distributions for the model parameters were selected as those utilised in Model C1; with $B_C \sim N(0, 1000)$. Note that the standard deviation κ is constant across classes and the model could be further extended to assume the B_C parameters are exchangeable across treatment classes rather than independent

Model fit and assessments

All models were implemented in WinBUGS [Version 1.4.3] [18]. The results were based on 600,000 simulations to ensure convergence of models. The first 100,000 simulations, classified as the “burn-in”, were discarded, with the next 500,000 simulations saved on which all results

are based. Convergence on models was assessed through visual inspection of the trace and history plots. Model fit was compared using deviance information criterion (DIC). DICs can be used in Bayesian analysis as a measure of model fit, with smaller values indicating a better fit [19]. Total residual deviance was also compared to the total number of independent data points in the dataset being analysed. The results were reported as mean difference (95% credible intervals [CrI]) for the treatment effects in comparison to the reference treatment (canagliflozin) and median standard deviations (SDs) with 95% CrIs. Note that placebo could not be selected as the reference treatment in the network as there were no non-randomised studies with the placebo and the structure of some of the models require a reference treatment that is common to both study designs.

Results

Systematic review and network structure

In total, 74 studies were included in this NMA (study flow chart reported in Appendix 1 of the [supplementary file](#)); 64 papers were RCTs and 10 studies were non-randomised. Of the 64 RCTs included in the analysis, 53 reported outcomes at only 24 weeks, seven reported outcomes at only 52 weeks and four reported outcomes at both 24 and 52 weeks. Of the included observational studies, five reported outcomes at 24 weeks only, two reported outcomes at 52 weeks only and three reported outcomes at both 24 and 52 weeks (which included the aggregate data from the CPRD). Figure 1 displays the network structures. At 24 weeks, 13 unique treatments were compared: placebo, four treatments within the SGLT-2i




Fig. 1 Network plots for the network meta-analysis of HbA1c (%) at 24 weeks and 52 weeks. Nodes represent treatments with sizes of the nodes proportional to the number of participants and the lines represent the direct comparisons between any two treatments with the width of the line proportional to the number of studies per contrast

class and eight treatments within the GLP-1RA class. The network was similar at 52 weeks, with the exception of taspoglutide being excluded due to no studies reporting outcomes at this time point for this treatment. The number of individuals with type 2 diabetes recruited to RCTs was on average 490 individuals (range: 50–2072 individuals) with observational studies on average studying larger populations (mean: 1863, range: 212–5141 individuals). List of references for the included studies is given in Additional file 1: Appendix 2 and the details of the studies, including the treatment arms, number of participants and the extracted data on treatment effects are reported in Appendix 3 of the supplementary file.

Naïve pooling

Figure 2, Table 1 (columns 2–4) and Table 2 (columns 2–4) report the mean differences (95% CrI), compared to the reference treatment canagliflozin, in change in HbA1c (%) from baseline after 24 and 52 weeks when analysing RCT data and observational data separately along with naïve pooling (Model A) method. Compared to placebo, the reference treatment canagliflozin reduced HbA1c by -0.72% (-0.84, -0.60) after 24 weeks and by

-0.69% (-0.94, -0.45) after 52 weeks when using the naïve pooling method. There was no meaningful difference found between canagliflozin and other SGLT-2is (dapagliflozin, empagliflozin and ertugliflozin) at 24 weeks. However, most GLP-1RAs reduced HbA1c by a greater amount than canagliflozin, with the greatest reduction seen in semaglutide (-0.77% (-1.08, -0.47)). There were no other differences observed at 52 weeks. For treatment comparisons available from both RCTs and observational studies, the point estimates for the treatment effect obtained from the naïve pooling were typically between the mean effects obtained from the NMAs carried out separately for RCTs and for the non-randomised studies. Some of these effects obtained with reduced uncertainty compared to the estimates from the RCT data alone. This reduction in uncertainty, however, was relatively small. For example, at 24 weeks the effect of dapagliflozin relative to canagliflozin was 0.17 (-0.01, 0.35) from RCT data alone and 0.01 (-0.13, 0.16) from the naïve pooling of both sources of evidence, reducing the width of the 95% CrI by 19.4%. At 52 weeks the improvement in precision was much more pronounced due to the higher uncertainty around the effectiveness estimate for this endpoint




Fig. 2 Network meta-analysis forest plots for analysis of HbA1c at 24 and 52 weeks using the naïve pooling method. Note that for some of the treatments evidence was available only from either RCTs or from the non-randomised studies (denoted by OBS)

Table 1 Mean difference from baseline (95% CrIs) for HbA1c (%) at 24 weeks for all models fitted vs reference treatment (canagliflozin) and median (95% CrIs) for the between-study standard deviation SD. Model A: naïve pooling, Model B1: two-level hierarchical model (treatment vs class), Model B2: two-level hierarchical model (treatment vs design), Model B3: three-level hierarchical model, Model C1: bias adjustment assuming the same bias by class, Model C2: bias adjustment allowing for bias to vary by class. ^aSGLT-2i therapies (the remaining treatments, apart from the placebo, are from the GLP-1RA class)

Treatment vs Canagliflozin	Model							
	RCT only	OBS only	Model A	Model B1	Model B2	Model B3	Model C1	Model C2
Effectiveness								
Dapagliflozin ^a	0.17 (-0.01, 0.35)	-0.22 (-0.41, -0.03)	0.01 (-0.13, 0.16)	-0.00 (-0.14, 0.14)	0.00 (-0.24, 0.23)	-0.02 (-0.22, 0.19)	0.04 (-0.12, 0.22)	0.10 (-0.05, 0.25)
Empagliflozin ^a	0.10 (-0.09, 0.30)	-0.37 (-0.70, -0.04)	-0.03 (-0.21, 0.15)	-0.03 (-0.19, 0.13)	-0.05 (-0.34, 0.20)	-0.05 (-0.28, 0.16)	0.00 (-0.19, 0.19)	0.03 (-0.13, 0.19)
Exenatide BID	0.18 (0.01, 0.35)	0.01 (-0.34, 0.38)	0.12 (-0.04, 0.28)	0.11 (-0.04, 0.27)	0.13 (-0.13, 0.39)	0.09 (-0.16, 0.32)	0.13 (-0.02, 0.29)	0.12 (-0.02, 0.26)
Lixisenatide	0.30 (0.13, 0.47)	0.34 (-0.04, 0.74)	0.27 (0.11, 0.43)	0.26 (0.1, 0.42)	0.31 (0.06, 0.59)	0.24 (-0.06, 0.48)	0.27 (0.11, 0.43)	0.25 (0.11, 0.39)
Albiglutide	-0.04 (-0.34, 0.25)	-0.36 (-0.70, -0.01)	-0.17 (-0.40, 0.06)	-0.17 (-0.39, 0.05)	-0.16 (-0.45, 0.13)	-0.15 (-0.41, 0.10)	-0.14 (-0.38, 0.10)	-0.13 (-0.34, 0.07)
Dulaglutide	-0.26 (-0.44, -0.07)	-0.48 (-0.77, -0.18)	-0.33 (-0.50, -0.17)	-0.33 (-0.49, -0.17)	-0.32 (-0.58, -0.07)	-0.3 (-0.52, -0.06)	-0.31 (-0.48, -0.15)	-0.33 (-0.47, -0.18)
Exenatide QW	-0.11 (-0.30, 0.08)	-0.30 (-0.57, 0.00)	-0.19 (-0.34, -0.02)	-0.19 (-0.34, -0.03)	-0.16 (-0.41, 0.09)	-0.16 (-0.37, 0.06)	-0.17 (-0.33, 0.00)	-0.18 (-0.32, -0.03)
Liraglutide	-0.25 (-0.42, -0.08)	-0.30 (-0.56, -0.03)	-0.27 (-0.41, -0.12)	-0.26 (-0.41, -0.12)	-0.24 (-0.48, 0.00)	-0.23 (-0.44, 0.01)	-0.28 (-0.43, -0.12)	-0.31 (-0.45, -0.18)
Placebo	0.78 (0.66, 0.91)	-	0.72 (0.60, 0.84)	0.72 (0.61, 0.84)	0.74 (0.44, 1.06)	0.74 (0.47, 1.08)	0.73 (0.61, 0.85)	0.73 (0.63, 0.83)
Ertugliflozin ^a	-0.06 (-0.28, 0.16)	-	-0.13 (-0.35, 0.09)	-0.08 (-0.3, 0.1)	-0.10 (-0.44, 0.25)	-0.07 (-0.34, 0.18)	-0.11 (-0.33, 0.10)	-0.11 (-0.30, 0.08)
Semaglutide	-0.71 (-1.01, -0.41)	-	-0.77 (-1.08, -0.47)	-0.67 (-0.97, -0.37)	-0.75 (-1.14, -0.35)	-0.58 (-0.95, -0.14)	-0.76 (-1.06, -0.46)	-0.76 (-1.04, -0.48)
Taspoglutide	-0.09 (-0.29, 0.11)	-	-0.15 (-0.36, 0.05)	-0.15 (-0.35, 0.04)	-0.13 (-0.46, 0.22)	-0.13 (-0.4, 0.14)	-0.14 (-0.34, 0.06)	-0.14 (-0.32, 0.04)
Class-level effects and bias								
D. SGLT-2i				-0.04 (-0.55, 0.46)		-0.05 (-0.66, 0.55)		
D. GLP-1RA				-0.17 (-0.48, 0.12)		-0.15 (-0.45, 0.14)		
Bias							0.06 (-0.09, 0.2)	
Bias. SGLT-2i								-0.24 (-0.43, -0.03)
Bias. GLP-1RA								0.13 (0.00, 0.25)
Heterogeneity								
SD	0.1 (0.04, 0.16)	0.04 (0.00, 0.17)	0.11 (0.07, 0.16)	0.11 (0.07, 0.16)	0.09 (0.03, 0.14)	0.09 (0.02, 0.14)	0.1 (0.05, 0.16)	0.08 (0.01, 0.13)
SD. SGLT-2i				0.1 (0.0, 1.78)		0.12 (0.0, 2.03)		
SD. GLP-1RA				0.33 (0.18, 0.7)		0.31 (0.12, 0.69)		
SD.design					0.11 (0.02, 0.28)	0.1 (0.02, 0.26)		
SD.bias							0.09 (0.0, 0.26)	0.04 (0.0, 0.15)

(smaller number of studies). At 24 weeks, the effects of dapagliflozin and empagliflozin appeared to be in conflict when comparing the results across the two study designs

(favouring the treatments compared to canagliflozin in the non-randomised studies but not in the RCTs). The estimated between-study heterogeneity differed across

Table 2 Mean difference from baseline (95% CrIs) for HbA1c (%) at 52 weeks for all models fitted vs reference treatment (canagliflozin) and median (95% CrIs) for the between-study standard deviation SD. Model A: naïve pooling, Model B1: two-level hierarchical model (treatment vs class), Model B2: two-level hierarchical model (treatment vs design), Model B3: three-level hierarchical model, Model C1: bias adjustment assuming the same bias by class, Model C2: bias adjustment allowing for bias to vary by class. ^aSGLT-2i therapies (the remaining treatments, apart from the placebo, are from the GLP-1RA class)

Treatment vs Canagliflozin	Model							
	RCT only	OBS only	Model A	Model B1	Model B2	Model B3	Model C1	Model C2
Effectiveness								
Dapagliflozin ^a	0.12 (-0.26, 0.55)	-0.18 (-1.12, 0.76)	0.06 (-0.23, 0.37)	0.03 (-0.27, 0.33)	0.01 (-0.72, 0.68)	-0.02 (-0.39, 0.34)	0.10 (-0.18, 0.40)	0.06 (-0.22, 0.34)
Empagliflozin ^a	-0.14 (-0.62, 0.40)	-0.24 (-1.21, 0.50)	-0.15 (-0.51, 0.20)	-0.12 (-0.47, 0.21)	-0.17 (-0.90, 0.53)	-0.14 (-0.53, 0.24)	-0.15 (-0.48, 0.20)	-0.15 (-0.45, 0.17)
Exenatide BID	-	0.20 (-0.86, 0.53)	0.32 (-0.28, 0.90)	0.14 (-0.32, 0.62)	0.27 (-0.84, 1.30)	0.08 (-0.4, 0.6)	0.49 (-0.46, 1.30)	0.14 (-0.80, 1.07)
Lixisenatide	-	0.17 (-0.66, 0.48)	0.18 (-0.24, 0.67)	0.1 (-0.28, 0.62)	0.14 (-0.89, 1.14)	0.04 (-0.4, 0.5)	0.24 (-0.40, 0.88)	-0.11 (-0.82, 0.66)
Dulaglutide	-	-0.07 (-0.94, 0.46)	-0.07 (-0.47, 0.36)	-0.05 (-0.42, 0.34)	-0.07 (-1.07, 0.93)	-0.06 (-0.49, 0.37)	0.05 (-0.66, 0.66)	-0.20 (-0.91, 0.48)
Exenatide QW	-0.03 (-0.61, 0.60)	0.18 (-0.70, 0.46)	0.14 (-0.23, 0.52)	0.14 (-0.42, 0.34)	0.10 (-0.64, 0.81)	0.08 (-0.32, 0.47)	0.10 (-0.30, 0.51)	-0.09 (-0.54, 0.37)
Liraglutide	-	0.17 (-0.62, 0.43)	0.19 (-0.16, 0.57)	0.14 (-0.21, 0.49)	0.18 (-0.83, 1.15)	0.07 (-0.36, 0.5)	0.08 (-0.49, 0.72)	-0.25 (-0.89, 0.47)
Placebo	0.71 (0.44, 1.04)	-	0.69 (0.45, 0.94)	0.71 (0.47, 0.96)	0.70 (-0.23, 1.66)	0.72 (0.28, 1.17)	0.70 (0.49, 0.94)	0.69 (0.49, 0.90)
Ertugliflozin ^a	-0.09 (-0.61, 0.48)	-	-0.11 (-0.60, 0.40)	-0.07 (-0.5, 0.35)	-0.10 (-1.10, 0.92)	-0.08 (-0.55, 0.39)	-0.10 (-0.53, 0.36)	-0.11 (-0.52, 0.31)
Albiglutide	-0.10 (-0.53, 0.34)	-	-0.12 (-0.52, 0.25)	-0.07 (-0.4, 0.31)	-0.11 (-1.07, 0.87)	-0.06 (-0.44, 0.35)	-0.11 (-0.45, 0.23)	-0.12 (-0.44, 0.19)
Semaglutide	-0.66 (-1.36, 0.09)	-	-0.49 (-1.01, 0.05)	-0.29 (-0.76, 0.26)	-0.59 (-1.69, 0.42)	-0.25 (-0.8, 0.28)	-0.54 (-1.03, 0.00)	-0.72 (-1.26, 0.18)
Class-level effects and bias								
d. SGLT-2i				-0.05 (-0.99, 0.85)		-0.08 (-1.05, 0.87)		
d. GLP-1RA				0.02 (-0.36, 0.41)		-0.01 (-0.4, 0.39)		
Bias							0.21 (-0.5, 0.8)	
Bias. SGLT-2i								-0.21 (-1.06, 0.61)
Bias. GLP-1RA								0.26 (-0.34, 0.78)
Heterogeneity								
SD	0.10 (0.01, 0.5)	0.27 (0.02, 1.04)	0.13 (0.01, 0.33)	0.14 (0.01, 0.33)	0.11 (0.01, 0.32)	0.11 (0.01, 0.3)	0.09 (0.00, 0.3)	0.08 (0.00, 0.28)
SD. SGLT-2i				0.23 (0.01, 2.7)		0.23 (0.01, 2.81)		
SD. GLP-1RA				0.23 (0.03, 0.64)		0.2 (0.01, 0.64)		
SD.design					0.21 (0.01, 1.38)	0.14 (0.01, 0.39) ^a		
SD.bias							0.19 (0.01, 0.62)	0.14 (0.01, 0.57)

the two sets of data (RCTs and non-randomised studies), in particular at 52 weeks where it was obtained with much greater uncertainty.

Hierarchical models

Estimated overall mean differences in change from baseline in HbA1c (%), compared to the reference treatment of canagliflozin, when utilising the hierarchical models

are reported in Table 1 (columns 5–7) for 24 weeks follow up time and Table 2 (columns 5–7) for 52 weeks follow up time. In comparison with the naïve-pooling method, hierarchical models provided similar effect estimates. The hierarchical model accounting for treatment classes (Model B1) resulted in the effect estimates with credible intervals similar to those obtained from the naïve-pooling model. However, the credible intervals were wider for the estimates from the hierarchical models allowing for differences in the study design (i.e. Model B2 and B3). For example, when considering the effect estimate for dapagliflozin in comparison to canagliflozin, the mean difference between the two treatments was close to 0 in all models. However, the estimate was obtained with a greater level of uncertainty in the two-level hierarchical model accounting for study design (0.00% (-0.24, 0.23)) and three-level hierarchical model (-0.02% (-0.27, 0.21)) in comparison to the two-level hierarchical model accounting for treatment classes (-0.01% (-0.15, 0.14)).

In all hierarchical models at 24 weeks, semaglutide showed the greatest reduction in HbA1c (%) in comparison to canagliflozin with a reduction of -0.71% (-1.00, -0.42) when using a two-level hierarchical model accounting for treatment classes and -0.75% reduction (-1.14, -0.35) when using a two-level hierarchical model accounting for study design. However, this reduction was smaller when using a three-level hierarchical model (-0.62% (-0.98, -0.12)) with increased uncertainty. This is likely to be due to the fact that the three-level hierarchical model takes into account the differences *between* treatments *within* classes of SGLT-2is and GLP-1RAs as well as the differences between study designs, allowing for additional variability.

Bias-adjustment models

When considering the bias adjustment models, Model C1 assumes the same level of bias for all treatments in observational studies, regardless of treatment class. In this

case, the effect estimates were similar to those obtained from the naïve pooling method. Further, these effect estimates had narrower credible intervals compared to those from the hierarchical models accounting for study design, as shown in Table 1 for the effect at 24 weeks and in Table 2 for the effect at 52 weeks. The bias term in this model was estimated to be 0.06 (-0.09, 0.20) at 24 weeks which suggests there was no substantial systematic discrepancy between RCT and observational studies (Table 1). However, when relaxing the assumption of the fully exchangeable bias and allowing the bias to vary across treatment classes (Model C2), the bias for SGLT-2is is estimated as -0.24 (-0.43, -0.03) and for GLP-1RAs as 0.13 (0.00, 0.25) at 24 weeks (Table 1). This suggests observational studies overestimated the effect of SGLT-2is by 0.24%, while GLP-1RAs were underestimated by 0.13%. While bias estimates differed across the two models, effect estimates and 95% credible intervals were similar (Tables 1 and 2), but slightly shifted in the direction of the bias. As observed in all other models, semaglutide showed the greatest reduction in HbA1c at 24 weeks in both bias-adjusted models (Model C1: -0.76% (-1.06, -0.46), Model C2: -0.76% (-1.04, -0.48)) (Table 1). There were no differences found at 52 weeks (Table 2); however, some of the estimates were obtained with reduced uncertainty compared to those from naïve pooling. For example, the effect of empagliflozin relative to canagliflozin at 52 weeks was -0.15 (-0.45, 0.17) from Model C2 and -0.15 (-0.51, 0.20) from naïve pooling.

Model assessments

Table 3 reports the DIC, residual difference and the total number of independent data points for each NMA model at 24 and 52 weeks. At 24 and 52 weeks, the naïve-pooling model had the poorest fit (24 week DIC: -161.78, 52 week DIC: -15.15) in comparison to the hierarchical and bias-adjustment models fitted. At 24 weeks, the bias adjusted model assuming varying bias by class (Model

Table 3 Measures of model fit for models including both RCT and non-randomised studies. Model A: naïve pooling, Model B1: two-level hierarchical model (treatment vs class), Model B2: two-level hierarchical model (treatment vs design), Model B3: three-level hierarchical model, Model C1: bias adjustment assuming same bias by class, Model C2: bias adjustment allowing for bias to vary by class

Model	DIC		Residual deviance		Total number of independent data points	
	24 weeks	52 weeks	24 weeks	52 weeks	24 weeks	52 weeks
Model A	-161.78	-15.15	134.3	39.65	137	38
Model B1	-172.94	-29.81	135.6	39.74		
Model B2	-174.26	-28.96	135.8	38.93		
Model B3	-173.81	-31.31	136.3	39.92		
Model C1	-171.15	-29.68	138.3	46.56		
Model C2	-175.68	-30.38	149.5	45.71		

C2) provided the best fit to the data according to the DIC (DIC: -175.68). However, the model showed poorest fit according to the residual deviance of 149.5 (compared to 137 data points) at 24 weeks. Both bias adjustment models had relatively large residual deviance at 52 weeks. The hierarchical models accounting for study design provided a good fit to the data in terms of both the DIC and residual deviance (two-level hierarchical model DIC: -174.26, three-level hierarchical model DIC: -173.81). At 52 weeks, the three-level hierarchical model accounting for treatment design and class provided the best fit to the data (DIC: -31.31), with the bias adjusted model varying the bias within classes also providing a good fit (DIC: -30.38). Hierarchical models accounting for the differences in the study design gave slightly lower between-study heterogeneity compared to the naïve pooling and the two level model with class effect, which, along with their good fit, suggests that these models may be preferred.

Discussion

The methods used in this study provide a basis for inclusion of aggregate data from comparative non-randomised studies in a systematic review and NMA of RCTs. A number of methods were explored and developed further, which included naïve pooling, hierarchical models accounting for the design of the studies and bias adjustment for observational studies. All methods were applied to an illustrative example in type 2 diabetes medications.

In this systematic review and NMA of RCTs and non-randomised studies, a total of 64 RCTs and 10 observational studies were analysed. In most cases, the direction of effect was similar in both RCT data and non-randomised data, which is supported by current research [20]. However, in contrast to the RCTs, the observational studies favoured two SGLT-2i therapies, compared to the reference treatment. Naïve-pooling averaged the effect estimate between what was observed in RCTs and non-randomised studies, with most effect estimates having similar or smaller credible intervals in comparison to the results of NMA of RCT data alone.

In order to account for the limitations of non-randomised studies, hierarchical models and bias adjusted models were explored. In this study, hierarchical models fitted accounted for the design of the study, which was further extended to consider the classification of treatments within the SGLT-2i and GLP-1RA class. As in previous studies [9, 21], effect estimates were similar to those from the naïve pooling method but credible intervals were often wider. In particular, allowing for additional heterogeneity across studies of different designs increased credible intervals. By allowing for additional levels of heterogeneity, the impact of the over-precision

of the estimates from the observational studies on the pooled effects may be reduced.

Bias adjusted models, applied to data from our example of type 2 diabetes, resulted in similar effect estimates, if slightly shifted to the direction of the bias, compared to the naïve pooling model. Similar to Dias et al. [15], between trial heterogeneity decreased when adjusting for bias, thus suggesting some of this heterogeneity was explained by the bias in observational studies. Interestingly, allowing bias to vary by class, relaxing the assumption that bias could be in the same direction regardless of treatment, models provided a better fit to the data according to DIC. This suggests that the magnitude and directionality of bias could differ by class and it may not be appropriate to assume the same bias for all observational studies.

Limitations

There are a number of limitations that need to be considered in this study. Firstly, this study has considered a single dataset and illustrative example. While this is a relatively large NMA, considering a number of treatments and studies, it included a relatively small number of non-randomised studies, which may have contributed excessively to the increased level of uncertainty. It is important to consider the effect of these models in alternative datasets, which may depend on a number of factors. Previously published studies showed similar effects as this study when utilising the naïve pooling model and hierarchical model accounting for study design [9, 21]. The results from this study are promising but would need further investigation to understand the implications in other datasets. Future studies should also consider using simulation to assess the performance of these methods under a range of scenarios. Secondly, the non-randomised studies included in the NMA on average contributed a larger proportion of individuals compared to RCTs. This could potentially lead to the increased impact of the non-randomised studies on the pooled effectiveness estimates, which is a limitation particularly in the presence of unmeasured confounding. Thirdly, the issue of double-counting of individuals in NMAs including observational studies was not considered in this study. As the number of real-world and observational studies using large electronic health care databases increase, it is likely that individuals could be included multiple times in evidence synthesis due to the same database being used or individuals included in the databases also taking part in RCTs, thus artificially inflating precision [22]. However, allowing for further heterogeneity across study designs and by introducing a bias factor, may mitigate the impact of this issue due to the allowance for increased uncertainty. Fourth, bias within RCTs was not considered in this NMA. Risk of bias assessment was completed in the original systematic review and NMA for RCTs. Most studies showed low risk of bias in

RCTs and so adjusting for bias in RCTs in this case may have minimal impact but further work could consider adjusting for bias within RCTs as well as observational studies by, for example, adapting a Bayesian mixture hierarchical model proposed by Verde [10] to an NMA and allowing for bias to vary according to treatment class. In fact, an extension of the model by Verde to NMA was recently proposed by Hamza et al., who also make software available to analysts [23]. Finally, this systematic review and NMA only considered aggregate level data for both RCTs and observational studies. It would be important to consider the extension of these methods when including IPD for both RCTs and observational studies, as recently proposed by Hamza et al. [23]. Moreover, further work could also consider the impact of the quality of the effectiveness estimates from the non-randomised studies when modelling bias. For example, there is likely heterogeneity in the way treatment effects are estimated and reported. Some studies may use appropriate methods of adjustment for confounding whereas others may not. Such information could also be used when deciding how to share the bias parameters; across the studies providing better quality estimates vs those of poorer quality.

Conclusions

The inclusion of observational data in NMAs of RCTs is gaining considerable traction in HTA due to the many benefits such as increasing evidence base, potentially connecting disconnected networks and allowing for more generalizable inferences. Methods such as hierarchical NMA and bias adjustment allow for more detailed modelling of the heterogeneity between study designs and can also be extended to allow for differences between treatment classes or account for differences in treatment doses. Both, hierarchical and bias adjustment models can provide a better fit to the data in comparison to naïve pooling and should be explored when conducting evidence synthesis. While the methods developed may ameliorate the effects of overestimation in observational studies, further analysis such as simulation studies would need to be conducted to investigate the capabilities of these models.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12874-023-01925-5>.

Additional file 1: Appendix 1. PRISMA flow chart of included randomised controlled trials and observational studies in the network meta-analysis. **Appendix 2.** List of references of the studies included in the network meta-analysis. **Appendix 3.** Table of data extracted from studies included in the network meta-analysis.

Acknowledgements

The authors would like to acknowledge authors of the original systematic review and NMA used as an illustrative example in this study; Professor Kamlesh Khunti, Dr Francesco Zaccardi, Professor Melanie J. Davies, Emily Patsko, Dr Nafeesa Dhalwani, David Kloecker and Ekaterini Ioannidou.

Authors' contributions

HH, SB, KRA and LJG conceived the article. HH and LJG undertook data curation. HH, SB, SD and SA conceptualised the models. HH carried out the formal analyses. SB and KRA provided supervision for HH. HH produced first draft of the manuscript. All authors contributed to manuscript revisions. The author(s) read and approved the final manuscript.

Funding

This research was funded by the Medical Research Council [grant no. MR/R025223/1]. The funders had no role in the design and conduct of the study, the collection, analysis, and interpretation of the data, or the preparation, review, or approval of the manuscript.

HH, LJG and SB were also supported by the National Institute for Health and Care Research (NIHR) Applied Research Collaboration East Midlands (ARC EM) and Leicester NIHR Biomedical Research Centre (BRC). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.

Availability of data and materials

All data generated or analysed during this study are included in this published article (and its supplementary information files).

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

KRA is a member of the National Institute for Health and Care Excellence (NICE) Diagnostics Advisory Committee, the NICE Decision and Technical Support Units, and is a National Institute for Health Research (NIHR) Senior Investigator Emeritus [NF-SI-0512-10159]. He has served as a paid consultant, providing unrelated methodological and strategic advice, to the pharmaceutical and life sciences industry generally, as well as to DHSC/NICE, and has received unrelated research funding from Association of the British Pharmaceutical Industry (ABPI), European Federation of Pharmaceutical Industries & Associations (EFPIA), Pfizer, Sanofi and Swiss Precision Diagnostics/Clearblue. He has also received course fees from the Association of the British Pharmaceutical Industry (ABPI) and is a Partner and Director of Visible Analytics Limited, a health technology assessment consultancy company. SD has received course fees from the ABPI.

SB is a member of the NICE Decision Support Unit. She has served as a paid consultant, providing methodological advice, to NICE, Roche, RTI Health Solutions and IQVIA, received payments for educational events from Roche and has received research funding from European Federation of Pharmaceutical Industries & Associations (EFPIA) and Johnson & Johnson. All other authors have no competing interest to declare.

Author details

¹BioStatistics Research Group, Department of Population Health Sciences, University of Leicester, University Road, Leicester LE1 7RH, UK. ²Department of Statistics, University of Warwick, Coventry CV4 7AL, UK. ³Centre for Health Economics, University of York, York YO10 5DD, UK. ⁴Centre for Reviews and Dissemination, University of York, York YO10 5DD, UK.

Received: 21 December 2022 Accepted: 14 April 2023

Published online: 22 April 2023

References

- Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al. Cochrane handbook for systematic reviews of interventions version 6.3 (updated February 2022). The Cochrane Collaboration; 2020. Available from: www.training.cochrane.org/handbook.
- Evans D. Hierarchy of evidence: a framework for ranking evidence evaluating healthcare interventions. *J Clin Nurs*. 2003;12(1):77–84.

3. Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ*. 2011;343:d5928.
4. Hill N, Frappier-Davignon L, Morrison B. The periodic health examination. *Can Med Assoc J*. 1979;121:1193–254.
5. Welton NJ, Sutton AJ, Cooper N, Abrams KR, Ades AE. Evidence synthesis for decision making in healthcare. Chichester: Wiley; 2012.
6. Sarri G, Patorno E, Yuan H, Guo JJ, Bennett D, Wen X, et al. Framework for the synthesis of non-randomised studies and randomised controlled trials: a guidance on conducting a systematic review and meta-analysis for healthcare decision making. *BMJ Evid Based Med*. 2022;27(2):109–19.
7. Dias S, Welton NJ, Sutton AJ, Ades A. NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. 2011. [Last Updated: September 2016]. Available from: <http://nicedsu.org.uk/technical-support-documents/evidence-synthesis-tsd-series/>.
8. Efthimiou O, Mavridis D, Debray TP, Samara M, Belger M, Siontis GC, et al. Combining randomized and non-randomized evidence in network meta-analysis. *Stat Med*. 2017;36(8):1210–26.
9. Schmitz S, Adams R, Walsh C. Incorporating data from various trial designs into a mixed treatment comparison model. *Stat Med*. 2013;32(17):2935–49.
10. Verde PE. A bias-corrected meta-analysis model for combining, studies of different types and quality. *Biom J*. 2021;63(2):406–22.
11. Verde PE, Ohmann C. Combining randomized and non-randomized evidence in clinical research: a review of methods and applications. *Res Synth Methods*. 2015;6(1):45–62.
12. Dias S, Sutton AJ, Welton NJ, Ades A. NICE DSU technical support document 3: heterogeneity: subgroups, meta-regression, bias and bias-adjustment. 2011.
13. Faria R, Alava MH, Manca A, Wailoo AJ. NICE DSU technical support document 17: the use of observational data to inform estimates of treatment effectiveness for Technology Appraisal: Methods for comparative individual patient data. 2015. Available from: <http://www.nicedsu.org.uk>.
14. Begg CB, Pilote L. A model for incorporating historical controls into a meta-analysis. *Biometrics*. 1991;47(3):899–906.
15. Dias S, Welton N, Marinho V, Salanti G, Higgins JP, Ades A. Estimation and adjustment of bias in randomized evidence by using mixed treatment comparison meta-analysis. *J R Stat Soc A Stat Soc*. 2010;173(3):613–29.
16. Hussein H, Zaccardi F, Khunti K, Davies MJ, Patsko E, Dhalwani NN, et al. Efficacy and tolerability of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis. *Diabetes Obes Metab*. 2020;22(7):1035–46.
17. Owen RK, Tincello DG, Abrams KR. Network meta-analysis: development of a three-level hierarchical modeling approach incorporating dose-related constraints. *Value Health*. 2015;18(1):116–26.
18. Lunn DJ, Thomas A, Best N, Spiegelhalter D. WinBUGS—a Bayesian modelling framework: concepts, structure, and extensibility. *Stat Comput*. 2000;10(4):325–37.
19. Spiegelhalter DJ, Best NG, Carlin BP, Van Der Linde A. Bayesian measures of model complexity and fit. *J R Stat Soc B Stat Methodol*. 2002;64(4):583–639.
20. Ioannidis JP, Haidich A-B, Pappa M, Pantazis N, Kokori SI, Tektonidou MG, et al. Comparison of evidence of treatment effects in randomized and nonrandomized studies. *JAMA*. 2001;286(7):821–30.
21. Jenkins DA, Hussein H, Martina R, Dequen-O'Byrne P, Abrams KR, Bujkiewicz S. Methods for the inclusion of real-world evidence in network meta-analysis. *BMC Med Res Methodol*. 2021;21(1):1–9.
22. Hussein H, Nevill CR, Meffen A, Abrams KR, Bujkiewicz S, Sutton AJ, et al. Double-counting of populations in evidence synthesis in public health: a call for awareness and future methodological development. *BMC Public Health*. 2022;22(1):1–10.
23. Hamza T, Chalkou K, Pellegrini F, Kuhle J, Benkert P, Lorscheider J, et al. Synthesizing cross-design evidence and cross-format data using network meta-regression. *Res Synth Methods*. 2023;14:283–300.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

